Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Gilead Sciences has announced a temporary halt to emergency access to its investigational Covid-19 drug remdesivir due to rising demand.
The antiviral drug is currently being assessed in several clinical trials for treating the novel coronavirus infection. For patients unable to participate in studies, the company has been working with regulators to offer emergency access to the drug.
Gilead noted that several hundred patients had been provided emergency access to remdesivir across the US, Europe and Japan.
However, a recent surge in Covid-19 cases in the US and Europe led to an ‘exponential increase’ in compassionate use requests, added the company. How